Who
Joaquin Duato
CEO and Chairman of the Board
Company insider
Files Form 4 as: CEO and Chairman of the Board, Johnson & Johnson; Director, Hess.
In numbers
- Trades disclosed
- 170
- Buys
- 1
- Sells
- 6
- Bought
- $25K
- Sold
- $168.2M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 10 Feb 2017
- Last trade
- 13 Aug 2026
- Last filed
- 14 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Aug 2026filed 14 Aug 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Code M | $14.3M123,291 at $115.67 | filing |
| 13 Aug 2026filed 14 Aug 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Sold | $5.5M20,976 at $262.00 | filing |
| 13 Aug 2026filed 14 Aug 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Sold | $26.7M102,315 at $261.00 | filing |
| 13 Aug 2026filed 14 Aug 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —123,291 at $0.00 | filing |
| 13 Aug 2026filed 14 Aug 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —123,291 at $0.00 | filing |
| 13 Aug 2026filed 14 Aug 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Code M | $14.3M123,291 at $115.67 | filing |
| 13 Aug 2026filed 14 Aug 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Sold | $5.5M20,976 at $262.00 | filing |
| 13 Aug 2026filed 14 Aug 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Sold | $26.7M102,315 at $261.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Sold | $10.8M41,957 at $258.06 | filing |
| 5 Aug 2026filed 7 Aug 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Sold | $1.7M6,523 at $258.74 | filing |
| 5 Aug 2026filed 7 Aug 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Sold | $10.8M41,957 at $258.06 | filing |
| 5 Aug 2026filed 7 Aug 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Sold | $1.7M6,523 at $258.74 | filing |
| 15 Feb 2026filed 18 Feb 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,682 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —4,505 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —131,734 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —9,459 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,682 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —4,505 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —131,734 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —9,459 at $0.00 | filing |
News
PepsiCo Elects Joaquin Duato to Board of Directorsprnewswire.com · 17 Sep 2026Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trialJNJ · indiatimes.com · 24 Oct 2026"No Industry Has Been as Criminal as Big Pharma": Gardiner Harris on Johnson & Johnson – Sri Lanka GuardianJNJ · slguardian.org · 24 Oct 2026Capital Group Core Balanced ETF (NYSE: CGBL) Opens New Position In Johnson & Johnson (NYSE: JNJ)JNJ · foreignpolicyjournal.com · 23 Oct 2026
1 headline in the last 90 days name Joaquin Duato; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.